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Asthma is the most common respiratory disorder, and is characterized by distal airway inflam-
mation and hyperresponsiveness. This disease challenges human health because of its
increasing prevalence, severity, morbidity, and the lack of a proper and complete cure.
Asthma is characterized by TH2eskewed inflammation with elevated pulmonary levels of IL-
4, IL-5, and IL-13 levels. Although there are early forays into targeting TH2 immunity, less-
specific corticosteroid therapy remains the immunomodulator of choice. Innate immune injury
mediated by complement components also act as potent mediators of the allergic inflamma-
tory responses and offer a new and exciting possibility for asthma immunotherapy. The com-
plement cascade consists of a number of plasma- and membrane-bound proteins, and the
cleavage products of these proteins (C3 and C5) regulate the magnitude of adaptive immune
responses. Complement protein are responsible for many pathophysiological features of
asthma, including inflammatory cell infiltration, mucus secretion, increases in vascular perme-
ability, and smooth muscle cell contraction. This review highlights the complement-mediated
injury during asthma inflammation, and how blockade of active complement mediators may
have therapeutic application.
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Asthma is a chronic inflammatory disease of the bronchi
arising because of inappropriate immunological responses
to common environmental antigens in genetically suscep-
tible individuals [1]. It is thought to be mediated by CD4þ T
lymphocytes that produce TH2 cytokines linked with
elevated specific IgE, eosinophilia, and airway hyper-
responsiveness (AHR) [2e4]. This perspective will explore
how an important component of the innate immunity, the
complement system, normally a key defense against
mucosal bacteria, viruses, fungi, helminthes, and other
pathogens, may also play an important role in the patho-
genesis of asthma. Although complement factors have been
associated with development of pathophysiology of asthma
[5,6], the role of individual complement components in the
pathogenesis of allergic asthma is not clear. Biologically
active fragments (C3a, C5a), generated through theMast cell 
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(Fig. 1), participate in AHR induction. Infections, and al-
lergens of respiratory tract activate local complement
activation participate in AHR [8e10] because of their ability
to recruit, activate leukocytes, increase vascular perme-
ability, stimulate contraction of smooth muscle, and trigger
degranulation of mast cells [9,11e13]. In addition to al-
lergens, other triggers of asthma have been shown to
activate complement cascade in human, and in animal
models [13]. It has been demonstrated that bronchoalveo-
lar lavage (BAL) of asthma individuals contain quantita-
tively higher levels of C3a and C5a as compared to healthy
control subjects at baseline [14].
In asthma, overproduction of activated complement
fragments may promote asthma susceptibility [13]. This
imbalance results in up regulation of biologically active
fragments, C3a and C5a, which may act on cells of theAlternative 
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Figure 2 Model explains Th1 to Th2 shift during the devel-
opment of asthma pathogenesis, and, C3a and C5a as a potential
targets to rescue asthma by blocking local T cell recruitment.
Complement components for asthma treatment 545innate immune system to favor asthma development [9,11].
The anaphylatoxins C3a and C5a have been characterized
as potent mediators of the effector phase of the allergic
response [8e10,15] with C3a regulating TH2 cytokine pro-
duction possibly through the recruitment, and activation of
TH2 cells [13]. C5a plays a dual immunoregulatory role by
protecting against the TH2-polarized adaptive immune
response and mediates type 2 inflammatory responses once
inflammation proceeds [13] (see Fig. 2). Complement may
participate in the development of susceptibility to asthma,
despite a normal level of complement fragments generated
during complement activation.
Different models of experimental allergic asthma sug-
gest that the C3a and C5a not only promote pro-allergic
effector functions during the allergic effector phase, but
also regulate the development of TH2 immunity during
allergen sensitization [16]. Generation of C3a on airway
surfaces induce TH2-mediated inflammatory responses to a
variety of environmental triggers of asthma (i.e., allergens,
pollutants, viral infections, cigarette smoke) [9,11]. C5a is
dominant during allergen sensitization, and protects
against the development of maladaptive TH2 immunity
[13,16]. By contrast, C3a and C5a appear to act synergis-
tically and drive allergic inflammation during the effector
phase [10]. In addition to its proinflammatory effector
functions, complement regulates adaptive immunity at
many levels [12], and play critical role as well in causing
vascular injury in allografts [17,18].
It has been observed that allergen challenged C3aR-
deficient mice and guinea pigs are protected against
bronchoconstriction and AHR [16]. Interestingly, there was
no difference in eosinophilic airway inflammation, TH2
cytokine production, IgE production between C3a receptor-
deficient, and in wild type animals which demonstrate that
airway inflammation, and AHR are two independent fea-
tures of asthma [2,3]. Several studies have demonstrated
that blocking of IL-4 reduces AHR in the lung, and that
RAG/ mice, which lack Th2 cells, fail to develop AHR,
mucus hyper-secretion, and eosinophilia during the course
of asthma [19]. However, airway inflammation, and the
immune responses at cellular and molecular levels have led
to the proposition of a number of mechanisms such as mast
cell degranulation [18,20,21], neurogenic dysfunction,involvement of T-lymphocytes, eosinophils, altered immu-
nosuppressive macrophages, excessive nitric oxide through
inducible nitric oxide synthase, overproduction of proin-
flammatory cytokines and immunoglobulins [22] during the
asthma development.
Asthmatic inflammation may be initiated or exacerbated
by amplification of the complement cascade [11e13].
Complement components, especially C5 and C3 with their
associated cleavage products C5a and C3a, regulate the
magnitude of adaptive immune responses via ligation of
their respective receptors expressed on antigen-presenting
cells, and T lymphocytes, as well as on pulmonary struc-
tures, and stromal cells [5,22]. These immune responses
involve many pathophysiological features of asthma that
include inflammatory cell infiltration, mucus secretion, in-
crease vascular permeability, and smooth muscle contrac-
tion [23]. This review summarizes the crucial role of
complement mediators in airway inflammation, and how it
affects the pathogenesis of asthma disease.Generation of c3a and c5a in asthma
Asthma is associated with activation of complement
cascade and allergen induced complement generates C3a
and C5a [3]. It has been demonstrated that C3a plays a
crucial role in asthma primarily by regulating mast cell-ASM
(Airway Smooth Muscle) cell interaction [14]. C3a and C5a
are released as key active factors in complement cascade
that modulate innate immunity [3,4]. C5a is, however,
involved in a number of inflammatory diseases [24] such as
immune-complex-mediated lung injury, microvascular
injury in rejecting allografts [20] and in sepsis [14]. Levels
of C3a are found elevated in bronchoalveolar lavage fluid
after allergen challenge in asthmatic but not among
healthy controls [3]. The C3a and C5a peptides regulate
inflammatory functions by interacting with their receptors
C3aR and C5aR [25,26]. These receptors were mostly pre-
sent only on myeloid cells such as macrophages, neutro-
phils, eosinophils, basophils, and mast cells, however, the
immune cells that express these receptors in the lung have
been investigated, and their expression been examined
during phase of asthma inflammation [27e30]. These find-
ings suggests the participation of bronchial epithelial and
smooth muscle cells in the pathology of diseases such as
sepsis and asthma, the data suggest a role for complement
receptors during lung inflammation [27].
It has been observed that C3aR activation is associated
with the development of AHR, and inflammation in
different animal models of asthma [27]. However, C3aR-
deficient mice are protected from AHR in response to
aerosolized ovalbumin challenge following intraperitoneal
sensitization with ovalbumin [31]. Single nucleotide poly-
morphisms in C3 and C3aR genes have been linked with
increased susceptibility to asthma [31]. This speculates the
crucial role of C3a and C3aR in the development of AHR and
inflammation [31]. BAL fluids of C3aR deficient mice also
had low levels of TH2 cytokines (IL-4, IL-5, and IL-13), IgE
titers, and mucous production that further support a role of
C3a receptors in the development of AHR, and generalized
inflammation [15,31,32]. It is observed that deficiency of
C3aR leads to decrease airway hyperresponsiveness in a
546 M.A. Khan et al.mouse model pulmonary allergy [32]. In addition, increased
C3a levels have been reported in bronchial lavage samples
from allergen-challenged asthma patients [3]. There is a
significant association has been reported between AHR and
C5 level [3], however, compared to C5 sufficient mice, the
C5-deficient mice are more responsive to methacholine
challenges after allergen exposure [33]. The presence of C5
and C5aR is necessary for a variety of immunological re-
sponses including inflammation and host defense [14].
Elevated levels of complement anaphylatoxin peptides
have been observed in the lungs of asthmatic patients [27]
which further supports the significance of complement
factors in asthma pathogenesis. The C5 gene and the C5aR
receptor genetic regions have been identified as putative
asthma susceptible loci [27]. Finally, C3aR and C5aR
expression has demonstrated on lung bronchial smooth
muscle cells implicating these receptors as mediators of
bronchoconstriction [34].Complement mediators-immune cell
interaction in asthma pathogenesis
Cells of the innate immune system in asthmatics are
abnormally responsive to the regulatory effects of com-
plement followed by the development of susceptibility to
asthma [10,35]. Recent research efforts have also demon-
strated that CD4þ T cells, which produce a TH2 pattern of
cytokines, play a pivotal role in the pathogenesis of this
disease [52] and cytokines such as IL-4, IL-13, and IL-5 to
contribute in bronchial hyper-reactivity, and mucus hyper-
secretion as well as orchestrate the recruitment, activation
of mast cells, and eosinophils [19,53,54]. The complement
cascade is a central player of innate immunity that co-
ordinates a number of inflammatory responses [35]. C3a
activates mast cells, basophils, eosinophils, and contrac-
tion of airway smooth muscle cell [18,24]. Both C3a and C5a
can induce ASM cell contraction, increase the microvascular
permeability, and regulate vasodilation [5]. C5a has been
widely used as standard stimulant to eosinophil/or basophil
responsivity, and active C5 fragments alone can induce
airway hyperresponsiveness when administered [24]. In
addition, C3a and C5a can: 1) stimulate respiratory burst in
macrophages, neutrophils, and eosinophils; 2) stimulate
the release of histamine from basophils and mast cells; and
3) regulate the synthesis of eosinophil cationic proteins and
adhesion to endothelial cells by eosinophils [14,20]. C3a
can also stimulate serotonin release from platelets, and
modulate synthesis of IL-6 and TNF-a by B-lymphocytes and
monocytes [36,37]. C5a is a potent chemotactic molecule
for macrophages, neutrophils, T lymphocytes, and baso-
phils [27]. Both C3a and C5a can induce chemotaxis of eo-
sinophils and mast cells [27]. Generation of C3a at the
airway surface triggers induction of AHR [13], while C5/
C5a, plays a dual immunoregulatory role by protecting
against the initiation of Th2-mediated immune responses
during initial allergen exposure by its ability to affect
dendritic cell-T cell interactions, and a more traditional
pro-inflammatory role once immune responses are estab-
lished [13,16].
The interactions between C5a and the IL-12 are impor-
tant for generating AHR-associated inflammation [38].Direct administration of IL-12 has shown to reduce AHR, and
macrophages from the C5-deficient mice were here shown
to produce lower levels than the control mice [39e42]. C3b
on the other hand, has been shown as capable of blocking
IL-12 production by its interaction with the aMb2 integrin,
an action perfectly in keeping with a positive role for C3
cleavage in AHR e either via C3a and its receptor or through
C3b and reduced levels of IL-12 [43].
C5 has been associated with dendritic cells mediated
induction of Tregs (CD4þCD25þ T cells) and Tregs blockade
in allergen exposed C5 sufficient mice eliminated their
protection from the development of AHR associated with a
drop in the numbers of pulmonary dendritic cells [13]. In
addition, depletion of dendritic cells and Tregs in mice
results in an increased capacity to stimulate T cell prolif-
eration and Th2 cytokine production. The balance between
C3a and C5a during early life exposures to allergens may be
a crucial determinant factor in the development of toler-
ance to inhaled antigens [9,13]. In lungs, C3 would most
probably create Th2 shift, which is consistent with data
suggesting that the lungs have Th2 type cell at birth in
newborn [44]. Clinical studies has shown the relatively
higher levels of C3a and C5a in BAL fluid of allergen induced
asthmatic airways as compared with control subjects
[5,10,16]. C5a contribute to the development of the pro-
allergic environment in allergic asthma [10], and targeting
C5 in allergen-induced asthma model have demonstrated
that C5 may serve as a suitable target in treatment of
asthma [10,45].
C5a can bind to both C5aR and C5L2 receptors [5], and,
more specifically C5L2 acts at the dendritic cell and T cells
interface, and control the development of TH1 and TH17
cells in response to airway antigen exposure, and drives TH2
immune responses independent of specific dendritic cells
[46]. As reported earlier, C5a, and perhaps C3a may cause
immediate airflow obstruction, and subsequent airway hy-
peractivity [27]. It has been demonstrated in murine model
of AHR that C5a may act directly or indirectly to stimulate
C5aR on local mast cells and/or platelets, resulting in the
release of broncho constrictive mediators, and results in
sensitization of the airways without cellular inflammation
[47]. In a number of other asthma models, the role of IL-17
has been highlighted in inducing asthmatic response, and
AHR [48]. There has been increasing evidence suggest the
involvement of C3a in the asthma pathogenesis, and the
relationship between C3a driven IL-17 and IgE-mediated
asthmatic responses that have shown the contribution of
IL-17 to an IgE-mediated late-phase asthmatic response,
and AHR [48]. They reported that during repeated antigen
exposure, C3a mediated antibody production (IgE) results in
production of IL-17þCD4þ cells in the lungs [18,24,49]
(Fig. 1).Summary
Asthma, a complex airway inflammatory disease, is char-
acterized by bronchoconstriction, AHR and airway remod-
elling [50]. Current consensus suggests that TH2 cytokine
producing T cells, mast cells, and ASM cells play central
roles in the pathogenesis of asthma [51]. This classification
of asthma has led to the concept that the immediate
Complement components for asthma treatment 547response after allergen challenge is mediated by mast cells,
whereas eosinophils are the predominant effector cells in
the late asthmatic reaction [27]. C3 and C5 play unique
roles in airway inflammation associated with asthma and
the release of C3a at the airway surface mediates the in-
duction of AHR in different asthma models, while C5/C5a
plays a dual immunoregulatory role by protecting against
Th2-mediated immune responses during initiation of re-
sponses, and a proinflammatory role once immune re-
sponses are established [50]. Serine proteases generated in
response to classical and alternative pathways has poten-
tial to generate C3a and C5a from C3 and C5 respectively
[55,56]. It is observed that different components of the
complement cascade have implicated in mediating allergic
inflammation [57]. As reported in other asthma models, C3a
and C5a participate in shifting Th2 and Th1 balance
respectively but blocking or antagonizing C5a shift response
to Th2 [13] and Th2 shift results in elevated Th2 adaptive
response followed by airway inflammation [42]. These
anaphylatoxins can induce ASM contraction [20,58,59],
mucus secretion [60,61], increased microvascular perme-
ability [62,63] [17,24], vasodilation [64,65], leukocyte
migration and activation, and degranulation of mast cells
[66], which are the hallmarks features of asthma. Further,
the most important, neutralization of anaphylatoxin activ-
ity through the use of blocking antibodies, genetic targeting
or by using specific antagonist of various complement fac-
tors or their receptors has been shown to attenuate allergic
inflammation, and AHR in mice, and guinea pigs [67,68]. It
is becoming increasingly clear that immunoregulatory
events occurring at the interface of innate and adaptive
immunity play an important role in asthma pathogenesis
[13]. The data reviewed here suggest that the complement
pathway serves as a central regulator of adaptive immune
responses to a variety of inhaled substances.
The complement cascade consists of number of serum
and cellular proteins, and the activation of complement
includes a series of initiation, amplification, and release of
active mediators that mediate cell lysis [35]. The whole
complement cascade is regulated at various points by
different complement regulatory proteins. These proteins
counter check the over expression of released active frag-
ments, make balance between self and foreign tissue, and,
therefore, allows for control over the potent tissue-
damaging capabilities of complement activation. Soluble,
and membrane-bound complement regulators have been
produced, and shown to be effective in blocking comple-
ment activation in vitro as well as in animal models of
complement-mediated pathologies in different diseases
[69]. Compared with conventional therapeutic options
available to asthma patients, recombinant proteins for
therapy remain attractive to date, for reasons having to do
with both the biological properties of proteins, and the
economics of drug development [18,24]. A number of
complement inhibitors has been introduced as therapeutic
agents for inflammatory, ischemic [70], and autoimmune
diseases [42]. It has been reported that Crry-Ig treatment
inhibit airway inflammation, and AHR in OVA sensitized
mice [9,11]. The objective here is to present a brief and
selective summary of the findings using synthetic molecules
for the therapeutic inhibition of complement in asthma
pathogenesis. In last couple of years, it has beenrecognized that some of the endogenous complement reg-
ulatory proteins has been proven to serve as potential
therapeutic agents in blocking inappropriate activation of
complement in human diseases specially asthma
[34,45,71,72]. In this review, our aim is to focus on more
translational approach in the field of asthma cure with the
possible use of novel complement inhibition approach to
control complement mediated airway injury, hyper-
responsiveness and ultimately to rescue asthma.Conflict of interest
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